Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infectionLaurie G. Jacobs, Judy L. Aschner, Elli Gourna Paleoudis et al.|PLoS ONE|2020Cited by 334
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational studyAndrew Ip, Stuart L. Goldberg, Urszula Bednarz et al.|PLoS ONE|2020Cited by 144
Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients – An Observational StudyAndrew Ip, Stuart L. Goldberg, Donald A. Berry et al.|medRxiv|2020Cited by 69